Combination study with our proprietary NASH-HCC model
We would like to introduce the combination study using NASH model mice.
| Combination study in NASH |
These days, a lot of pharmaceutical companies are trying to conduct combination studies for NASH.
Since NASH shows a variety of symptoms like steatosis, inflammation and fibrosis, pharmaceutical companies expect synergistic effect through administration of drug candidates which effect different targets.
| Combination study using STAM model |
We have patented NASH-HCC model, STAM model which is characterized by a similar disease progression to human NASH (fatty liver → NASH → liver fibrosis → HCC). The STAM model has been used for a lot of combination studies, including the following study using a SGLT2 inhibitor and DPP-4 inhibitor, expecting synergistic effect [Jojima T et al., Diabetol Metab Syndr., 2016].
Please see the following study plan.
In this study, we observed the improvement of the many parameters especially fibrosis in the combination therapy group compared to the effect of the monotherapies.
We believe that combination studies could be worth conducting as a method to expand the possibilities of your drug candidates.
If you have any drug candidates which you would like to investigate the efficacy against NASH, why not consider using our STAM model for your research and development projects? You can speed up development by commissioning highly specialized testing, which gives you the time to develop further drugs.
As you know, we have a variety of pathological models related to inflammation/fibrosis, as well as the STAM model. For more information, please contact us.